Integrated BioSci Investing: A Season Greeting From Dr. Tran BioSci

Summary

• We're what we are today due to the support of our community of expert readers, who are physicians, scientists, market leaders, fund managers, analysts, executives, and everyday investors.
• We're greatly appreciative of your stock tips, advice, wisdom, partnership, and friendship.
• We're continuing to learn and to grow. Merry Christmas and a Happy Holiday to you all.

We've grown much over the years (especially this year) as we’re blessed with a growing community of expert readers, who we view as teachers, business partners, and friends. Despite that we deliver the analytical research and consulting to you, we also learn significantly from your insight, wisdom, and suggestions in the process. Many of our followers are highly accomplished professionals, including physicians, scientists, professors, hedge fund managers, analysts, and executives, as well as other market leaders. We owe you our gratitude, especially Mr. Jacky Xiao, CEO Abelardo Fraga, Drs. Thomas Valdez and Zach Hartman, as well as many others. Much appreciation for teaching us and growing with us as partners.

Figure 1: Dr. Tran BioSci Logo. (Source: Dr. Tran BioSci of Integrated BioSci Investing).

It has been a blessing, as we've made mostly winning calls that greatly benefitted our community. Nektar Therapeutics (NASDAQ:NKTR) appreciated over 210%, Spectrum Pharmaceuticals (NASDAQ:SPPI) delivers over 170% profits, Kite Pharma (NASDAQ:KITE) procured over 82%, Exelixis (NASDAQ:EXEL) banked in over 50%, just to name a few. Our expert interviewing guests, including Biotech Beast, Decision Analytics, and Terry Chrisomalis made stellar calls that profited our readers substantially. And, we are greatly appreciative of their wisdom.

We’re also thankful for Seeking Alpha, Seeking Alpha editors, Robyn Conti, and Daniel Shvartsman for their ongoing guidance and support. In addition, we wish to send our gratitude to Richard Berger, who had advised us on how to grow our marketplace ("MP"). We recommend that you join his MP, Engineered Income Investing. The former executive is wise and has a strong track record of performance.

Figure 2: Notable BioSci Performers. (Source: Google Finance)

Of note, there are many companies we’re featuring in our MP that are highly likely to appreciate substantially in 2018 and for years to come. If you have yet to sign up with Integrate BioSci Investing, right now is a good time to do so to lock in the legacy price (as we're raising the price soon). And, we're implementing stellar developments. Much excitement to come.

On the behalf of Integrated BioSci Investing, we wish you and your family a Merry Christmas and a Happy Holiday. May this season fill you with joy.

Figure 3: Christmas Greeting. (Source: Christmas WallPaper)

Author Note: We're honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics procured more than 210% profits while Spectrum Pharmaceuticals (SPPI) delivered over 180% gains. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, we'll increase prices soon. Subscribe to our Marketplace research now to lock in the legacy price and save money in the future.To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and click on the orange "Follow" button. Besides the exclusives, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by following this link.

An Integrated BioSci Research On Crispr Therapeutics: The Future Of Individualized Medicine

Summary

• CRISPR is the revolutionary method of genes editing that can potentially treat a vast number of genetic diseases.
• The company is also brewing its own line of promising CAR-Ts.
• The partnership with Vertex to access its extensive resources. Fifty percent ownership of Casebia Therapeutics with Bayer to broaden the firm’s pipeline.
• Abundant cash to fund development for the next two years.
• This is the exclusive article for subscribers that we decided to publish earlier this week.

Since Oct. 28, 2016, shares of Crispr Therapeutics (NASDAQ:CRSP), a bioscience firm, focusing on the development and commercialization of gene editing and CAR-T to treat cancers and genetic diseases increased by $5.61 to trade at $19.48 for  (over 40% profits). Of note, the recent FDA approval of the two CAR-T products - tisagenlecleucel (Kymriah) of Novartis (NYSE:NVS) for the treatment of refractory acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta) of Gilead (NASDAQ:GILD) for resistant non-Hodgkin lymphomas - opened doors to similar therapeutics. With such exciting developments, Crispr’s share price would have been trading at much higher valuation without the patent litigation issue. In this report, we’ll explicate the company’s stellar technology (gene editing and CAR-T) while going over the patent concern, the robust financials as well as the superb management.

Figure 1: Crispr stock chart. (Source: StockCharts)

Author’s Notes: The full Integrated BioSci Research is available to subscribers of our marketplace service, Integrated BioSci Investing(where we also deliver in-depth consulting and key market-moving catalyst events).

Integrated BioSci Investing: A 2017 Thanksgiving Note

Summary

• Our marketplace is growing to deliver increasing value to subscribers.
• Spectrum Pharmaceuticals is the top performer. Second comes Nektar Therapeutics. Our portfolio is also powered by many other key winners.
• Kite Pharma was bought out in the recent months.
• We wish to send our Happy Thanksgiving to all readers, subscribers, and SA.
• Subscribe to our marketplace service to receive higher level intelligence, to galvanize your portfolio.

For the past 52-weeks, the Biotechnology Index (NASDAQ:IBB) gained 9.75% while key performers in our Integrated BioSci Investing portfolio posted profits far more robust. Kite Pharma (NASDAQ:KITE), now a subsidiary of Gilead Sciences (NASDAQ:GILD) delivered over 247% returns. Spectrum Pharmaceuticals (NASDAQ:SPPI) appreciated over 361%. Nektar Therapeutics (NASDAQ:NKTR) headed north over 250%. And, Amicus Therapeutics (NASDAQ:FOLD) procured over 51% profits.

Source: Google Finance (Notable Small-Caps BioSci Winners)

In 2013, we joined the ride with Seeking Alpha (and in May 2017, we decided to exclusively focus on our bioscience expertise). Since the commencement of our marketplace service (Integrated BioSci Investing) in the past five months, our overall recommendations to subscribers have been highly profitable (especially with key performers, as mentioned above).

For Thanksgiving 2017, we wish to send our appreciation to all readers (and especially subscribers as well as Seeking Alpha) for your readership, friendship, advice, and business. There are many highly intelligent subscribers, who enjoy the mutual learning. Going forward, we hope to continue to deliver our stellar service to you. Thank you all, and Happy Thanksgiving!

Source: Everyday Good Thinking

Omeros Corporation: Strong Earnings And Further Upsides

Summary

• Omeros reported strong Q3 sales growth for Omidria.
• The FDA granted orphan drug designation for OMX-721, a highly promising molecule that can be a key growth driver.
• With improving prospects, the company can continue to deliver substantial further upsides.

We recently interviewed the stellar trader scientist, Biotech Beast (“BB”) in our Integrated BioSci Investing interview series. In the discussion, BB recommended Omeros Corporation (NASDAQ:OMER) to investors. Based in Seattle, WA, the company is focusing on the development and commercialization of small-molecule and protein therapeutics for larger as well as orphan markets (targeting inflammation, complement-mediated diseases, and disorders of the central nervous system).

Source: StockCharts

Today, the stock popped over 32% due to strong Q3 earnings. Shares traded up $4.44 at $18.53 as of 3:30 pm ET. Accordingly, sales of lead eyes product, Omidria (indicated for use during cataract and lens replacement surgeries) came in at $21.7M. The aforesaid figure represents 26% and 125% improvement versus last quarter and the same quarter a year prior, respectively. Moreover, cash position improved to $86.8M plus the ability to borrow an additional $45M from existing lenders. Furthermore, the company also settled the patent infringement lawsuit against Par Pharmaceutical Companies (NYSE:PRX) on the favorable term in Oct. 2017.

Of note, we asked BB in the interview, 

Back in August, you published a balanced and insightful research on Omeros Corporation (NASDAQ:OMER). Notably, their lead ophthalmologic drug, Omidria, doesn’t generate robust sales. Would sales significantly increase in the future? And, are there other catalysts (or molecules in the pipeline) that can substantially improve the company’s prospects?

The expert, BB, stated that sales of Omidria might increase. Better yet, we are most interested in his response regarding a stellar molecule-in-development, OMS-721.

OMS-721 is the pipeline member which has attracted attention from investors and traders. We should be seeing more data from additional patients in the phase 2 IgA nephropathy trial of OMS-721 in early 2018 (and soon after results from a phase 3 trial in the same indication). Positive results from these additional patients in the phase 2 study will surely be well received (and bode well for the outcomes of the phase 3 study). Of note, data from the first cohort of patients in phase 2 were positive.

Notably, OMS-721, a molecule used to treat the kidney disease IgA nephropathy. Based on the company’s recent meeting with the FDA, approval can be achieved with only a single phase 3 trial: this will reduce significant expenses and expedite the approval. More importantly, the agency designated OMX-721 as an orphan drug (which will enable the company to charge a premium pricing, thus increasing its prospects substantially). Despite the risks of negative trial data, the increasing sales of Omidria and the orphan designation for OMS-721 are certainly promising developments. And, it is not far from the truth that much value remains in this company. Time will unfold more truth. 

Stay tuned for our analysis of this exciting bioscience winner. And, be sure to check out our Marketplace, Integrated BioSci Investing for the latest bioscience trading catalysts.